	US 11,725,186 B2
	Recombinant NK cells expressing co-stimulatory molecules
Patrick Soon-Shiong, Culver City, CA (US); Kayvan Niazi, Encino, CA (US); and Shahrooz Rabizadeh, Los Angeles, CA (US)
Assigned to Nant Holdings IP, LLC, Culver City, CA (US)
Filed by NANT HOLDINGS IP, LLC, Culver City, CA (US)
Filed on Dec. 3, 2019, as Appl. No. 16/702,275.
Application 16/702,275 is a division of application No. 15/366,838, filed on Dec. 1, 2016, granted, now 10,533,157.
Claims priority of provisional application 62/262,867, filed on Dec. 3, 2015.
Prior Publication US 2020/0109366 A1, Apr. 9, 2020
Int. Cl. A61K 35/17 (2015.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/735 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C07K 14/715 (2006.01); C12N 15/85 (2006.01)

CPC C12N 5/0646 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 45/06 (2013.01); C07K 14/7051 (2013.01); C07K 14/70535 (2013.01); C07K 14/715 (2013.01); C07K 16/30 (2013.01); C12N 15/85 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/572 (2013.01); C07K 2317/622 (2013.01); C07K 2319/70 (2013.01); C12N 2510/00 (2013.01)]

20 Claims

1. A method of treating a patient having a cancer, comprising:

administering a genetically engineered natural killer cell to the patient;

wherein the genetically engineered natural killer cell includes a recombinant nucleic acid that comprises

a first promoter region operably linked to at least three coding sequences, each encoding a neoepitope or an immune stimulating cytokine; and

a second promoter region operably linked to at least three coding sequences, each encoding at least a portion of at least one co-stimulatory molecule.